Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. [electronic resource]
Producer: 20140909Description: 647-51 p. digitalISSN:- 1879-2472
- Anticoagulants -- economics
- Cohort Studies
- Cost-Benefit Analysis
- Female
- Humans
- Male
- Markov Chains
- Middle Aged
- Morpholines -- economics
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Rivaroxaban
- Thiophenes -- economics
- United States
- Venous Thromboembolism -- economics
- Warfarin -- economics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.